TruScreen Group Limited Share Price

Current Share Price data for TruScreen Group Limited (NZX:TRU ASX:TRU)

NZX Listing
ASX Listing
Investing in TruScreen is an opportunity to invest in the future health and wellbeing of women around the world.

Cervical cancer can and should be prevented.

TruScreen provides an accurate, real-time primary screening solution. 
Our screening solution is ideal for communities that can’t access conventional laboratory-based screening methods. It is affordable and easy to learn.

Our purpose is to ensure that all women of screening age – no matter who or where they are – have access to quality screening.

TruScreen manufactures and owns all rights to the TruScreen Cervical Cancer Screening System. The system comprises a medical device and AI-enabled process designed to detect, in real-time, the presence of pre-cancerous and cancerous tissue on the cervix.

TruScreen’s focus markets are low and-middle income countries (LMICs) where there is a lack of organised cervical cancer screening and the required infrastructure.

Find out more about the company

TruScreen Latest NZX & ASX Announcements

General | Progress Report

TruScreen Makes Progress in Key Markets Worldwide

TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to provide a market update, outlining the Company’s progress in several of its key target markets.


TruScreen Half Year Report

TruScreen Group Limited - Interim Unaudited Financial Statements For the Six Months Ended 30 September 2021


TruScreen Half Year Results

TruScreen Group Limited is pleased to announce its unaudited half year financial results for the period ended 30 September 2021. TruScreen reports according to the New Zealand financial year, which runs from 1 April to 31 March.


TruScreen Device - Milestones Achieved on Growth Strategy

TruScreen Group Limited is pleased to announce the achievement of key milestones relating to the ongoing development of the Company’s women’s health care technology and its overseas growth strategy.


Clinical Trial Results Highlight Efficacy of TRU Technology

TruScreen Group Limited is pleased to inform the market of a study conducted in China, the results of which indicate that TruScreen’s cervical cancer screening technology has demonstrated to be an effective alternative to cervical cytology.


Director and Officer Disclosure Notice

Director and Officer Disclosure Notice - Dexter Cheung


Recording of TruScreen Group Limited Virtual ASM

The Annual Shareholder Meeting of Truscreen Group Limited (NZX:TRU) was held online on 7 September 2021 on Link Market Services virtual platform.


Shareholder Meeting Results

The Annual Meeting of Shareholders of Truscreen Group Limited (NZX:TRU)(ASX:TRU) was held today 7 September 2021. All resolutions were passed by a poll of shareholders present and by registered proxy.


Annual Meeting Presentation

The attached presentation will be delivered at the Annual Meeting of Shareholders to be held today at 11am New Zealand time


TruScreen Stakeholder August Newsletter

This gives an update on TruScreen's performance and highlights key initiatives underway.


Notice of General Meeting

Notice is hereby given that the Annual Meeting of Shareholders of Truscreen Group Limited will be held as a virtual meeting Online on Tuesday 7 September 2021 at 11.00am, Auckland time.


Chairman's Letter

I am pleased to invite shareholders to the 2021 Annual Meeting (AM) of TruScreen Group Limited. scheduled for 7 September 2021.


First Sales Made In Eastern Europe

TruScreen is pleased to advise that it has received its first order from Serbia, Eastern Europe.


TruScreen Annual Report 31 March 2021

TruScreen Limited (NZX: TRU) has released its Annual Report for the year ended 31 March 2021.


CEO Interview with Stocks Down Under

TruScreen CEO Juliet Hull, sat down and spoke to Stocks Down Under about the opportunity for the TruScreen technology in emerging markets to provide a lower cost and more patient-friendly alternative for cervical cancer screening.


Stakeholder May Newsletter

This gives an update on TruScreen's performance and highlights key initiatives underway.


Research Confirms TruScreen's Suitability in COVID-19 Environment

TruScreen is pleased to report that its TruScreen cervical cancer screening device continues to gain recognition around the world.

TruScreen Group Limited Announcements

TruScreen Group is dual-listed on the NZX and ASX.  All of our announcements are available through our website, or via the NZX and ASX platforms.

View announcements

Meet the Team

TruScreen has a wealth of experienced, highly skilled professionals across its Directors, Executive Team, Medical Advisory Board, and Research & Development Team.


TruScreen Team